EA201891240A1 - 1,3,4-тиадиазольные соединения и их применение в лечении рака - Google Patents

1,3,4-тиадиазольные соединения и их применение в лечении рака

Info

Publication number
EA201891240A1
EA201891240A1 EA201891240A EA201891240A EA201891240A1 EA 201891240 A1 EA201891240 A1 EA 201891240A1 EA 201891240 A EA201891240 A EA 201891240A EA 201891240 A EA201891240 A EA 201891240A EA 201891240 A1 EA201891240 A1 EA 201891240A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tiadiazolic
cancer
compounds
treatment
application
Prior art date
Application number
EA201891240A
Other languages
English (en)
Inventor
Морис Реймонд Верскойл Финлей
Йоханнес Вилхелмус Мария Ниссинк
Марк Дэвид Чарльз
Джеймс Мэттью Вуд
Original Assignee
Астразенека Аб
Кэнсер Рисерч Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб, Кэнсер Рисерч Текнолоджи Лимитед filed Critical Астразенека Аб
Publication of EA201891240A1 publication Critical patent/EA201891240A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Соединение формулы (I) или его фармацевтически приемлемая соль, где Q может представлять собой 5-метилпиридазин-3-ил, 5-хлорпиридазин-3-ил, 6-метилпиридазин-3-ил или 6-фторпиридазин-3-ил; R может представлять собой водород, фтор или метокси; Rможет представлять собой водород, метокси, дифторметокси или трифторметокси и Rможет представлять собой метил или этил. Соединение формулы (I) может ингибировать глутаминазу, например GLS1.
EA201891240A 2015-11-30 2016-11-30 1,3,4-тиадиазольные соединения и их применение в лечении рака EA201891240A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260787P 2015-11-30 2015-11-30
PCT/EP2016/079251 WO2017093300A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
EA201891240A1 true EA201891240A1 (ru) 2018-11-30

Family

ID=57421876

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891240A EA201891240A1 (ru) 2015-11-30 2016-11-30 1,3,4-тиадиазольные соединения и их применение в лечении рака

Country Status (25)

Country Link
US (1) US9938265B2 (ru)
EP (1) EP3383871B1 (ru)
JP (1) JP6873132B2 (ru)
KR (1) KR20180083412A (ru)
CN (1) CN108349967B (ru)
AR (1) AR106876A1 (ru)
AU (1) AU2016363719B2 (ru)
BR (1) BR112018010812A2 (ru)
CA (1) CA3005516C (ru)
CL (1) CL2018001408A1 (ru)
CO (1) CO2018006929A2 (ru)
DK (1) DK3383871T3 (ru)
DO (1) DOP2018000134A (ru)
EA (1) EA201891240A1 (ru)
ES (1) ES2759940T3 (ru)
IL (1) IL258644A (ru)
MX (1) MX2018006528A (ru)
NI (1) NI201800065A (ru)
PE (1) PE20181450A1 (ru)
PH (1) PH12018501132A1 (ru)
SG (1) SG11201803813UA (ru)
SV (1) SV2018005701A (ru)
TN (1) TN2018000126A1 (ru)
TW (1) TW201730188A (ru)
WO (1) WO2017093300A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10323028B2 (en) * 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
ES2939506T3 (es) * 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642237B1 (en) * 1999-11-24 2003-11-04 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
US8003806B2 (en) * 2004-11-12 2011-08-23 OSI Pharmaceuticals, LLC Integrin antagonists useful as anticancer agents
SI2421826T1 (sl) * 2009-04-20 2014-02-28 F. Hoffmann-La Roche Ag Derivati prolina kot inhibitorji katepsina
EP2782570B1 (en) * 2011-11-21 2019-09-18 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
PT2920168T (pt) * 2012-11-16 2021-10-18 Calithera Biosciences Inc Inibidores heterocíclicos de glutaminase
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
EP3092236B1 (en) * 2014-01-06 2020-08-26 Rhizen Pharmaceuticals S.A. Novel glutaminase inhibitors
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
TN2018000126A1 (en) 2019-10-04
IL258644A (en) 2018-06-28
JP2019501134A (ja) 2019-01-17
NI201800065A (es) 2018-10-18
AR106876A1 (es) 2018-02-28
ES2759940T3 (es) 2020-05-12
SV2018005701A (es) 2018-11-27
ES2759940T8 (es) 2020-05-20
AU2016363719A8 (en) 2018-07-12
EP3383871B1 (en) 2019-09-11
US9938265B2 (en) 2018-04-10
WO2017093300A1 (en) 2017-06-08
CA3005516C (en) 2024-04-16
EP3383871A1 (en) 2018-10-10
AU2016363719A1 (en) 2018-07-05
TW201730188A (zh) 2017-09-01
CA3005516A1 (en) 2017-06-08
CL2018001408A1 (es) 2018-10-12
PE20181450A1 (es) 2018-09-12
KR20180083412A (ko) 2018-07-20
CO2018006929A2 (es) 2018-10-10
SG11201803813UA (en) 2018-06-28
PH12018501132A1 (en) 2019-01-21
CN108349967A (zh) 2018-07-31
DOP2018000134A (es) 2018-06-30
US20170152254A1 (en) 2017-06-01
AU2016363719B2 (en) 2019-11-14
MX2018006528A (es) 2019-05-15
BR112018010812A2 (pt) 2018-11-27
CN108349967B (zh) 2022-02-15
JP6873132B2 (ja) 2021-05-19
DK3383871T3 (da) 2019-12-16

Similar Documents

Publication Publication Date Title
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
GEP20237506B (en) Pcsk9 antagonist compounds
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
UA111382C2 (uk) Інгібітори протеїнкінази
TN2018000119A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
EA201791304A1 (ru) Производные изохинолина для лечения вич
MX2017004600A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
EA201692470A1 (ru) Фармацевтические комбинации
EA201891241A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
PH12019500875A1 (en) Pyridone compound as c-met inhibitor
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
EA201891239A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
EA201492104A1 (ru) Ингибитор jak1/2
MX2018001317A (es) Inhibidores del virus sincitial respiratorio.
PH12018501132A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
MX2018006374A (es) Compuestos de bis-piridazina y su uso en el tratamiento del cancer.
MD3288949T2 (ro) Derivați de aminohidrothiazină fuzionați cu tetrahidrofuran utili în tratamentul bolii Alzheimer